|
|
Volumn 23, Issue 31, 2005, Pages 8134-8136
|
|
Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective study [17]
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIRETROVIRUS AGENT;
BENZODIAZEPINE;
ESZOPICLONE;
LAMIVUDINE;
NATALIZUMAB;
NEVIRAPINE;
ROFECOXIB;
ZIDOVUDINE;
ZOPICLONE;
PIPERAZINE DERIVATIVE;
ADDICTION;
ANUS CARCINOMA;
BRAIN LYMPHOMA;
BREAST ADENOCARCINOMA;
CANCER;
CANCER INCIDENCE;
CARCINOGENESIS;
CHROMOSOME ABERRATION;
COMBINATION CHEMOTHERAPY;
DAYTIME SOMNOLENCE;
DRUG EFFICACY;
DRUG SAFETY;
FIBROMA;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HODGKIN DISEASE;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
KAPOSI SARCOMA;
LETTER;
LUNG ADENOMA;
LUNG CARCINOMA;
LUNG NON SMALL CELL CANCER;
NONHUMAN;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
SARCOMA;
THYROID ADENOMA;
THYROID FOLLICULAR CARCINOMA;
WITHDRAWAL SYNDROME;
CHEMICALLY INDUCED DISORDER;
FEMALE;
HUMAN IMMUNODEFICIENCY VIRUS 1;
INCIDENCE;
MALE;
NEOPLASM;
PATHOGENICITY;
PATHOLOGY;
FEMALE;
HIV INFECTIONS;
HIV-1;
HUMANS;
INCIDENCE;
MALE;
NEOPLASMS;
PIPERAZINES;
|
|
EID: 32944474745
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2005.03.5881 Document Type: Letter |
|
Times cited : (11)
|
|
References (10)
|
